|
Sernova Corp. (TSX-V:SVA) is a Canadian based health sciences company focused on commercialization of innovative medical technologies. Its lead project is Sertolin, a technology for reversing insulin dependent diabetes through transplanted pig islet and Sertoli cells. The islet cells produce insulin that is compatible with human bodies while the Sertoli cells protect the islet cells from attack by the person's immune system. Sernova has the exclusive right to the patents and associated intellectual property for the therapeutic use of Sertoli cells in the United States, Canada and most major industrialized nations.
Dr. David White - Principal Researcher |
Follow the link to listen to a recent interview with Dr. White in which he discusses the primary causes and effects of diabetes as well as the work being done through xenotransoplantation in an attempt to restore those affected back to health: Audio Interview
|
| |
Aug 13, 2008: News Releases: Sernova Corp.'s Diabetes Technology Featured at International Congress of t... (more...)
Jul 30, 2008: News Releases: Appointment of New Officers (more...)
May 06, 2008: News Releases: Sernova Concludes Successful Pre-IND Meeting with FDA (more...)
| |
